Abstract
Viral fitness has been broadly studied during the past three decades, mainly to test evolutionary models and population theories difficult to analyze and interpret with more complex organisms. More recent studies, however, are focused in the role of fitness on viral transmission, pathogenesis, and drug resistance. Here, we used human immunodeficiency virus (HIV) as one of the most relevant models to evaluate the importance of viral quasispecies and fitness in HIV evolution, population dynamics, disease progression, and potential clinical implications.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Addo MM, Altfeld M, Rosenberg ES, Eldridge RL, Philips MN, Habeeb K, Khatri A, Brander C, Robbins GK, Mazzara GP, Goulder PJ, Walker BD (2001) The HIV-1 regulatory proteins Tat and Rev are frequently targeted by cytotoxic T lymphocytes derived from HIV-1-infected individuals. Proc Natl Acad Sci U S A 98:1781ā1786
Aebischer T, Moskophidis D, Rohrer UH, Zinkernagel RM, Hengartner H (1991) In vitro selection of lymphocytic choriomeningitis virus escape mutants by cytotoxic T lymphocytes. Proc Natl Acad Sci U S A 88:11047ā11051
Agrawal AF (2001) Sexual selection and the maintenance of sexual reproduction. Nature (London) 411:692ā695
Allen TM, OāConnor DH, Jing P, Dzuris JL, Mothe BR, Vogel TU, Dunphy E, Liebl ME, Emerson C, Wilson N, Kunstman KJ, Wang X, Allison DB, Hughes AL, Desrosiers RC, Altman JD, Wolinsky SM, Sette A, Watkins DI (2000) Tat-specific cytotoxic T lymphocytes select for SIV escape variants during resolution of primary viraemia. Nature (London) 407:386ā390
Altfeld M, Rosenberg ES, Shankarappa R, Mukherjee JS, Hecht FM, Eldridge RL, Addo MM, Poon SH, Phillips MN, Robbins GK, Sax PE, Boswell S, Kahn JO, Brander C, Goulder PJ, Levy JA, Mullins JI, Walker BD (2001) Cellular immune responses and viral diversity in individuals treated during acute and early HIV-1 infection. J Exp Med 193:169ā180
Anderson RM, May RM (1986) The invasion, persistence and spread of infectious diseases within animal and plant communities. Philos Trans R Soc Lond B Biol Sci 314:533ā570
Anderson RM, May RM (1992) Infectious diseases in humans: dynamics and control. Oxford University Press, Oxford
Anderson RM, May RM (1996) The population biology of the interaction between HIV-1 and HIV-2: coexistence or competitive exclusion? AIDS 10:1663ā1673
Archer RH, Dykes C, Gerondelis P, Lloyd A, Fay P, Reichman RC, Bambara RA, Demeter LM (2000) Mutants of human immunodeficiency virus type 1 (HIV-1) reverse transcriptase resistant to nonnucleoside reverse transcriptase inhibitors demonstrate altered rates of RNase H cleavage that correlate with HIV-1 replication fitness in cell culture. J Virol 74:8390ā8401
Armand-Ugon M, QuiƱones-Mateu ME, Gutierrez A, Barretina J, Blanco J, Schols D, De Clercq E, Clotet B, Este JA (2003) Reduced fitness of HIV-1 resistant to CXCR4 antagonists. Antivir Ther 8:1ā8
Arts EJ, Wainberg MA (1996) Mechanisms of nucleoside analog antiviral activity and resistance during human immunodeficiency virus reverse transcription. Antimicrob Agents Chemother 40:527ā540
Arts EJ, QuiƱones-Mateu ME, Albright JL, Marois JP, Hough C, Gu Z, Wainberg MA (1998) 3ā²-Azido-3ā²-deoxythymidine (AZT) mediates cross-resistance to nucleoside analogs in the case of AZT-resistant human immunodeficiency virus type 1 variants. J Virol 72:4858ā4865
Asjƶ B, Morfeldt-Manson L, Albert J, Biberfeld G, Karlsson A, Lidman K, Fenyƶ EM (1986) Replicative capacity of human immunodeficiency virus from patients with varying severity of HIV infection. Lancet ii:660ā662
Back NK, Nijhuis M, Keulen W, Boucher CA, Oude Essink BO, van Kuilenburg AB, van Gennip AH, Berkhout B (1996) Reduced replication of 3TC-resistant HIV-1 variants in primary cells due to a processivity defect of the reverse transcriptase enzyme. EMBO J 15:4040ā4049
Ball SC, Abraha A, Collins KR, Marozsan AJ, Baird H, QuiƱones-Mateu ME, Penn-Nicholson A, Murray M, Richard N, Lobritz M, Zimmerman PA, Kawamura T, Blauvelt A, Arts EJ (2003) Comparing the ex vivo fitness of CCR5-tropic human immunodeficiency virus type 1 isolates of subtypes B and C. J Virol 77:1021ā1038
Barbour JD, Hecht FM, Wrin T, Segal MR, Ramstead CA, Liegler TJ, Busch MP, Petropoulos CJ, Hellmann NS, Kahn JO, Grant RM (2004) Higher CD4+ T cell counts associated with low viral pol replication capacity among treatment-naive adults in early HIV-1 infection. J Infect Dis 190:251ā256
Barouch DH, Kunstman J, Kuroda MJ, Schmitz JE, Santra S, Peyerl FW, Krivulka GR, Beaudry K, Lifton MA, Gorgone DA, Montefiori DC, Lewis MG, Wolinsky SM, Letvin NL (2002) Eventual AIDS vaccine failure in a rhesus monkey by viral escape from cytotoxic T lymphocytes. Nature (London) 415:335ā339
Barton NH, Charlesworth B (1998) Why sex and recombination? Science 281:1986ā1990
Bates M, Wrin T, Huang W, Petropoulos C, Hellmann N (2003) Practical applications of viral fitness in clinical practice. Curr Opin Infect Dis 16:11ā18
Berger EA, Murphy PM, Farber JM (1999) Chemokine receptors as HIV-1 coreceptors: roles in viral entry, tropism, and disease. Annu Rev Immunol 17:657ā700
Bergstrom CT, McElhany P, Real LA (1999) Transmission bottlenecks as determinants of virulence in rapidly evolving pathogens. Proc Natl Acad Sci USA 96:5095ā5100
Berkhout B (1999) HIV-1 evolution under pressure of protease inhibitors: climbing the stairs of viral fitness. J Biomed Sci 6:298ā305
Bjorndal A, Deng H, Jansson M, Fiore JR, Colognesi C, Karlsson A, Albert J, Scarlatti G, Littman DR, Fenyo EM (1997) Coreceptor usage of primary human immunodeficiency virus type 1 isolates varies according to biological phenotype. J Virol 71:7478ā7487
Blaak H, Brouwer M, Ran LJ, de Wolf F, Schuitemaker H (1998) In vitro replication kinetics of human immunodeficiency virus type 1 (HIV-1) variants in relation to virus load in long-term survivors of HIV-1 infection. J Infect Dis 177:600ā610
Blackard JT, Renjifo B, Fawzi W, Hertzmark E, Msamanga G, Mwakagile D, Hunter D, Spiegelman D, Sharghi N, Kagoma C, Essex M (2001) HIV-1 LTR subtype and perinatal transmission. Virology 287:261ā265
Blauvelt A, Glushakova S, Margolis LB (2000) HIV-infected human Langerhans cells transmit infection to human lymphoid tissue ex vivo. AIDS 14:647ā651
Bleiber G, Munoz M, Ciuffi A, Meylan P, Telenti A (2001) Individual contributions of mutant protease and reverse transcriptase to viral infectivity, replication, and protein maturation of antiretroviral drug-resistant human immunodeficiency virus type 1. J Virol 75:3291ā3300
Bonhoeffer S, Chappey C, Parkin NT, Whitcomb JM, Petropoulos CJ (2004) Evidence for positive epistasis in HIV-1. Science 306:1547ā1550
Boots M, Sasaki A (1999) āsmall worldsā and the evolution of virulence: infection occurs locally and at a distance. Proc R Soc Lond B Biol Sci 266:1933ā1938
Borman AM, Paulous S, Clavel F (1996) Resistance of human immunodeficiency virus type 1 to protease inhibitors: selection of resistance mutations in the presence and absence of the drug. J Gen Virol 77:419ā426
Braathen LR, Ramirez G, Kunze RO, Gelderblom H (1987) Langerhans cells as primary target cells for HIV infection. Lancet 2:1094
Brambilla A, Turchetto L, Gatti A, Bovolenta C, Veglia F, Santagostino E, Gringeri A, Clementi M, Poli G, Bagnarelli P, Vicenzi E (1999) Defective nef alleles in a cohort of hemophiliacs with progressing and nonprogressing HIV-1 infection. Virology 259:349ā368
Bremermann HJ, Pickering J (1983) A game-theoretical model of parasite virulence. J Theor Biol 100:411ā426
Buhler B, Lin YC, Morris G, Olson AJ, Wong CH, Richman DD, Elder JH, Torbett BE (2001) Viral evolution in response to the broad-based retroviral protease inhibitor TL-3. J Virol 75:9502ā9508
Bull JJ (1994) Virulence. Evolution 48:1423ā1437
Burch CL, Chao L (1999) Evolution by small steps and rugged landscapes in the RNA virus phi6. Genetics 151:921ā927
Burch CL, Chao L (2000) Evolvability of an RNA virus is determined by its mutational neighbourhood. Nature (London) 406:625ā628
Burch CL, Chao L (2004) Epistasis and its relationship to canalization in the RNA virus phi 6. Genetics 167:559ā567
Burch CL, Turner PE, Hanley KA (2003) Patterns of epistasis in RNA viruses: a review of the evidence from vaccine design. J Evol Biol 16:1223ā1235
Cao J, McNevin J, Holte S, Fink L, Corey L, McElrath MJ (2003) Comprehensive analysis of human immunodeficiency virus type 1 (HIV-1)-specific gamma interferon-secreting CD8+ T cells in primary HIV-1 infection. J Virol 77:6867ā6878
Cao Y, Qin L, Zhang L, Safrit J, Ho DD (1995) Virologic and immunologic characterization of long-term survivors of human immunodeficiency virus type 1 infection. N Eng J Med 332:201ā208
Carotenuto P, Looij D, Keldermans L, de Wolf F, Goudsmit J (1998) Neutralizing antibodies are positively associated with CD4+ T-cell counts and T-cell function in long-term AIDS-free infection. AIDS 12:1591ā1600
Carrington M, Nelson GW, Martin MP, Kissner T, Vlahov D, Goedert JJ, Kaslow R, Buchbinder S, Hoots K, OāBrien SJ (1999) HLA and HIV-1: heterozygote advantage and B*35-Cw*04 disadvantage. Science 283:1748ā1752
Cecilia D, Kulkarni SS, Tripathy SP, Gangakhedkar RR, Paranjape RS, Gadkari DA (2000) Absence of coreceptor switch with disease progression in human immunodeficiency virus infections in India. Virology 271:253ā258
Chan DC, Fass D, Berger JM, Kim PS (1997) Core structure of gp41 from the HIV envelope glycoprotein. Cell 89:263ā273
Chao L (1990) Fitness of RNA virus decreased by Mullerās ratchet [see comments]. Nature (London) 348:454ā455
Cheng-Mayer C, Seto D, Tateno M, Levy JA (1988) Biologic features of HIV-1 that correlate with virulence in the host. Science 240:80ā82
Chouquet C, Autran B, Gomard E, Bouley JM, Calvez V, Katlama C, Costagliola D, Riviere Y (2002) Correlation between breadth of memory HIV-specific cytotoxic T cells, viral load and disease progression in HIV infection. AIDS 16:2399ā2407
Clarke DK, Duarte EA, Elena SF, Moya A, Domingo E, Holland J (1994) The red queen reigns in the kingdom of RNA viruses. Proc Natl Acad Sci U S A 91:4821ā4824
Clavel F, Race E, Mammano F (2000) HIV drug resistance and viral fitness. Adv Pharmacol 49:41ā66
Cocchi F, DeVico AL, Garzino-Demo A, Arya SK, Gallo RC, Lusso P (1995) Identification of RANTES, MIP-1 alpha, and MIP-1 beta as the major HIV-suppressive factors produced by CD8+ T cells [see comments]. Science 270:1811ā1815
Coffin JM (1986) Genetic variation in AIDS viruses. Cell 46:1ā14
Coffin JM (1995) HIV population dynamics in vivo: implications for genetic variation, pathogenesis, and therapy. Science 267:483ā489
Collins JA, Thompson MG, Paintsil E, Ricketts M, Gedzior J, Alexander L (2004) Competitive fitness of nevirapine-resistant human immunodeficiency virus type 1 mutants. J Virol 78:603ā611
Cooper VS, Reiskind MH, Miller JA, Shelton KA, Walther BA, Elkinton JS, Ewald PW (2002) Timing of transmission and the evolution of virulence of an insect virus. Proc R Soc Lond B Biol Sci 269:1161ā1165
Cornelissen M, Mulder-Kampinga G, Veenstra J, Zorgdrager F, Kuiken C, Hartman S, Dekker J, van Der HL, Sol C, Coutinho R (1995) Syncytium-inducing (SI) phenotype suppression at seroconversion after intramuscular inoculation of a nonsyncytium-inducing/SI phenotypically mixed human immunodeficiency virus population. J Virol 69:1810ā1818
Croteau G, Doyon L, Thibeault D, McKercher G, Pilote L, Lamarre D (1997) Impaired fitness of human immunodeficiency virus type 1 variants with high-level resistance to protease inhibitors. J Virol 71:1089ā1096
Crotty S, Cameron CE, Andino R (2001) RNA virus error catastrophe: direct molecular test by using ribavirin. Proc Natl Acad Sci U S A 98:6895ā6900
Cuevas JM, Moya A, Sanjuan R (2005) Following the very initial growth of biological RNA viral clones. J Gen Virol 86:435ā443
Dalod M, Dupuis M, Deschemin JC, Goujard C, Deveau C, Meyer L, Ngo N, Rouzioux C, Guillet JG, Delfraissy JF, Sinet M, Venet A (1999) Weak anti-HIV CD8(+) T-cell effector activity in HIV primary infection. J Clin Invest 104:1431ā1439
Daniel MD, Kirchhoff F, Czajak SC, Sehgal PK, Desrosiers RC (1992) Protective effects of a live attenuated SIV vaccine with a deletion in the nef gene [see comments]. Science 258:1938ā1941
De Maria A, Moretta L (2000) HLA-class I-specific inhibitory receptors in HIV-1 infection. Hum Immunol 61:74ā81
De Ronde A, van Dooren M, van Der HL, Bouwhuis D, de Rooij E, van Gemen B, de Boer R, Goudsmit J (2001) Establishment of new transmissible and drug-sensitive human immunodeficiency virus type 1 wild types due to transmission of nucleoside analogue-resistant virus. J Virol 75:595ā602
De Visser JA, Hoekstra RF, van de Ende H (1997) Test of interaction between genetic markers that affect fitness in Aspergillus niger. Evolution 51:1499ā1505
Deacon NJ, Tsykin A, Solomon A, Smith K, Ludford-Menting M, Hooker DJ, McPhee DA, Greenway AL, Ellet A, Chatfield C, Lawson VA, Crowe S, Maerz A, Sonza S, Learmont J, Sullivan JS, Cunningham A, Dwyer D, Dowton D, Mills J (1995) Genomic structure of an attenuated quasispecies of HIV-1 from a blood transfusion donor and recipients. Science 270:988ā991
Dean M, Carrington M, Winkler C, Huttley GA, Smith MW, Allikmets R, Goedert JJ, Buchbinder SP, Vittinghoff E, Gomperts E, Donfield S, Vlahov D, Kaslow R, Saah A, Rinaldo C, Detels R, OāBrien SJ (1996b) Genetic restriction of HIV-1 infection and progression to AIDS by a deletion allele of the CKR5 structural gene. Hemophilia Growth and Development Study, Multicenter AIDS Cohort Study, Multicenter Hemophilia Cohort Study, San Francisco City Cohort, ALIVE Study. Science 273:1856ā1862
Deeks SG (2001) International perspectives on antiretroviral resistance. Nonnucleoside reverse transcriptase inhibitor resistance. J Acquir Immune Defic Syndr 26Suppl 1:S25āS33
Deeks SG (2003) Treatment of antiretroviral-drug-resistant HIV-1 infection. Lancet 362:2002ā2011
Deeks SG, Barbour JD, Martin JN, Swanson MS, Grant RM (2000) Sustained CD4+ T cell response after virologic failure of protease inhibitor-based regimens in patients with human immunodeficiency virus infection. J Infect Dis 181:946ā953
Deeks SG, Wrin T, Liegler T, Hoh R, Hayden M, Barbour JD, Hellmann NS, Petropoulos CJ, McCune JM, Hellerstein MK, Grant RM (2001) Virologic and immunologic consequences of discontinuing combination antiretroviral-drug therapy in HIV-infected patients with detectable viremia. N Engl J Med 344:472ā480
Demeter LM, Shafer RW, Meehan PM, Holden-Wiltse J, Fischl MA, Freimuth WW, Para MF, Reichman RC (2000) Delavirdine susceptibilities and associated reverse transcriptase mutations in human immunodeficiency virus type 1 isolates from patients in a phase I/II trial of delavirdine monotherapy (ACTG 260). Antimicrob Agents Chemother 44:794ā797
Derdeyn CA, Decker JM, Sfakianos JN, Wu X, OāBrien WA, Ratner L, Kappes JC, Shaw GM, Hunter E (2000) Sensitivity of human immunodeficiency virus type 1 to the fusion inhibitor T-20 is modulated by coreceptor specificity defined by the V3 loop of gp120. J Virol 74:8358ā8367
Derdeyn CA, Decker JM, Bibollet-Ruche F, Mokili JL, Muldoon M, Denham SA, Heil ML, Kasolo F, Musonda R, Hahn BH, Shaw GM, Korber BT, Allen S, Hunter E (2004) Envelope-constrained neutralization-sensitive HIV-1 after heterosexual transmission. Science 303:2019ā2022
Deval J, White KL, Miller MD, Parkin NT, Courcambeck J, Halfon P, Selmi B, Boretto J, Canard B (2004) Mechanistic basis for reduced viral and enzymatic fitness of HIV-1 reverse transcriptase containing both K65R and M184V mutations. J Biol Chem 279:509ā516
Devereux HL, Emery VC, Johnson MA, Loveday C (2001) Replicative fitness in vivo of HIV-1 variants with multiple drug resistance-associated mutations. J Med Virol 65:218ā224
Domingo E, Holland JJ (1997) RNA virusmutations and fitness for survival. Annu Rev Microbiol 51:151ā178
Domingo E, EscarmĆs C, Sevilla N, Moya A, Elena SF, Quer J, Novella IS, Holland JJ (1996) Basic concepts in RNA virus evolution. FASEB J 10:859ā864
Domingo E, Menendez-Arias L, QuiƱones-Mateu ME, Holguin A, Gutierrez-Rivas M, Martinez MA, Quer J, Novella IS, Holland JJ(1997) Viral quasispecies and the problem of vaccine-escape and drug-resistant mutants. Prog Drug Res 48:99ā128
Domingo E, Escarmis C, Menendez-Arias L, Holland J (1999) Viral quasispecies and fitness variations. In: Domingo E, Webster R, Holland J (eds) Origin and evolution of viruses. Academic Press, San Diego, pp. 141ā161
Doyon L, Croteau G, Thibeault D, Poulin F, Pilote L, Lamarre D (1996) Second locus involved in human immunodeficiency virus type 1 resistance to protease inhibitors. J Virol 70:3763ā3769
Duarte E, Clarke D, Moya A, Domingo E, Holland J (1992) Rapid fitness losses in mammalian RNA virus clones due to Mullerās ratchet. Proc Natl Acad Sci U S A 89:6015ā6019
Duarte EA, Novella IS, Weaver SC, Domingo E, Wain-Hobson S, Clarke DK, Moya A, Elena SF, de la Torre JC, Holland JJ (1994) RNA virus quasispecies: significance for viral disease and epidemiology. Infect Agents Dis 3:201ā214
Dueweke TJ, Pushkarskaya T, Poppe SM, Swaney SM, Zhao JQ, Chen IS, Stevenson M, Tarpley WG (1993) A mutation in reverse transcriptase of bis(heteroaryl)piperazine-resistant human immunodeficiency virus type 1 that confers increased sensitivity to other nonnucleoside inhibitors. Proc Natl Acad Sci U S A 90:4713ā4717
Dyer WB, Ogg GS, Demoitie MA, Jin X, Geczy AF, Rowland-Jones SL, McMichael AJ, Nixon DF, Sullivan JS (1999) Strong human immunodeficiency virus (HIV)-specific cytotoxic T-lymphocyte activity in Sydney Blood Bank Cohort patients infected with nef-defective HIV type 1. J Virol 73:436ā443
Eastman PS, Mittler J, Kelso R, Gee C, Boyer E, Kolberg J, Urdea M, Leonard JM, Norbeck DW, Mo H, Markowitz M (1998) Genotypic changes in human immunodeficiency virus type 1 associated with loss of suppression of plasma viral RNA levels in subjects treated with ritonavir (Norvir) monotherapy. J Virol 72:5154ā5164
Eckert DM, Malashkevich VN, Hong LH, Carr PA, Kim PS (1999) Inhibiting HIV-1 entry: discovery of D-peptide inhibitors that target the gp41 coiled-coil pocket. Cell 99:103ā115
Elena SF (1999) Little evidence for synergism among deleterious mutations in a nonsegmented RNA virus. J Mol Evol 49:703ā707
Elena SF (2001) Evolutionary history conditions the timing of transmission in vesicular stomatitis virus. Infect Genet Evol 1:151ā159
Elena SF, Lenski RE (1997) Test of synergistic interactions amongdeleteriousmutations in bacteria. Nature (London) 390:395ā398
Elena SF, Gonzalez-Candelas F, Novella IS, Duarte EA, Clarke DK, Domingo E, Holland JJ, Moya A (1996) Evolutionoffitness in experimentalpopulationsof vesicular stomatitis virus. Genetics 142:673ā679
Elena SF, Sanjuan R, Borderia AV, Turner PE (2001) Transmission bottlenecks and the evolution of fitness in rapidly evolving RNA viruses. Infect Genet Evol 1:41ā48
Escarmis C, Davila M, Charpentier N, Bracho A, Moya A, Domingo E (1996) Genetic lesions associated with Mullerās ratchet in an RNA virus. J Mol Biol 264:255ā267
Escarmis C, Carrillo EC, Ferrer M, Arriaza JF, Lopez N, Tami C, Verdaguer N, Domingo E, Franze-Fernandez MT (1998) Rapid selection in modified BHK-21 cells of a foot-and-mouth disease virus variant showing alterations in cell tropism. J Virol 72:10171ā10179
Eshel I, Feldman MW (1970) On the evolutionary effect of recombination. Theor Popul Biol 1:88ā100
Esnouf R, Ren J, Ross C, Jones Y, Stammers D, Stuart D (1995) Mechanism of inhibition of HIV-1 reverse transcriptase bynon-nucleoside inhibitors. Nat Struct Biol 2:303ā308
Essex M (1999) Human immunodeficiency viruses in the developing world. Adv Virus Res 53:71ā88
Etemad-Moghadam B, Rhone D, Steenbeke T, Sun Y, Manola J, Gelman R, Fanton JW, Racz P, Tenner-Racz K, Axthelm MK, Letvin NL, Sodroski J (2002) Understanding the basis of CD4(+) T-cell depletion in macaques infected by a simian-human immunodeficiency virus. Vaccine 20:1934ā1937
Evans DT, OāConnor DH, Jing P, Dzuris JL, Sidney J, da Silva J, Allen TM, Horton H, Venham JE, Rudersdorf RA, Vogel T, Pauza CD, Bontrop RE, DeMars R, Sette A, Hughes AL, Watkins DI (1999) Virus-specific cytotoxic T-lymphocyte responses select for amino-acid variation in simian immunodeficiency virus Env and Nef. Nat Med 5:1270ā1276
Ewald PW (1993) The evolution of virulence. Sci Am 268:86ā93
Ewald PW (1994) Evolution of infectious diseases. Oxford University Press, New York
Fenner F, Kessler H (1994) Evolution of the poxviruses, including the coevolution of virus and host myxomatosis. In: Morse SS (ed) The evolutionary biology of viruses. Raven Press, New York, pp 273ā292
Fenyo EM, Albert J, Asjo B (1989) Replicative capacity, cytopathic effect and cell tropism of HIV. AIDS 3Suppl 1:S5āS12
Fenyo E, Schuitemaker H, Asjƶ B, McKeating J, Sattentau Q (2000) EC concerted action HIV variability. The history of HIV-1 biological phenotypes. Past, present and future. Review in 1997 Human Retroviruses and AIDS Compendium
Fikkert V, Van Maele B, Vercammen J, Hantson A, Van Remoortel B, Michiels M, Gurnari C, Pannecouque C, De Maeyer M, Engelborghs Y, De Clercq E, Debyser Z, Witvrouw M (2003) Development of resistance against diketo derivatives of human immunodeficiency virus type 1 by progressive accumulation of integrase mutations. J Virol 77:11459ā11470
Froissart R, Wilke CO, Montville R, Remold SK, Chao L, Turner PE (2004) Co-infection weakens selection against epistatic mutations in RNA viruses. Genetics 168:9ā19
Frost SD, Nijhuis M, Schuurman R, Boucher CA, Brown AJ (2000) Evolution of lamivudine resistance in human immunodeficiency virus type 1-infected individuals: the relative roles of drift and selection. J Virol 74:6262ā6268
Gallant JE, Gerondelis PZ, Wainberg MA, Shulman NS, Haubrich RH, St Clair M, Lanier ER, Hellmann NS, Richman DD (2003) Nucleoside and nucleotide analogue reverse transcriptase inhibitors: a clinical review of antiretroviral resistance. Antivir Ther 8:489ā506
Gandhi RT, Wurcel A, Rosenberg ES, Johnston MN, Hellmann N, Bates M, Hirsch MS, Walker BD (2003) Progressive reversion of human immunodeficiency virus type 1 resistance mutations in vivo after transmission of a multiply drug-resistant virus. Clin Infect Dis 37:1693ā1698
Gao F, Bailes E, Robertson DL, Chen Y, Rodenburg CM, Michael SF, Cummins LB, Arthur LO, Peeters M, Shaw GM, Sharp PM, Hahn BH (1999) Origin of HIV-1 in the chimpanzee Pan troglodytes troglodytes [see comments]. Nature (London) 397:436ā441
Gao X, Nelson GW, Karacki P, Martin MP, Phair J, Kaslow R, Goedert JJ, Buchbinder S, Hoots K, Vlahov D, OāBrien SJ, Carrington M (2001) Effect of a single amino acid change in MHC class I molecules on the rate of progression to AIDS. N Engl J Med 344:1668ā1675
Garcia-Lerma JG, Gerrish PJ, Wright AC, Qari SH, Heneine W (2000) Evidence of a role for the Q151L mutation and the viral background in development of multiple dideoxynucleoside-resistant human immunodeficiency virus type 1. J Virol 74:9339ā9346
Garcia-Lerma JG, MacInnes H, Bennett D, Weinstock H, Heneine W (2004) Transmitted human immunodeficiency virus type 1 carrying the D67N or K219Q/E mutation evolves rapidly to zidovudine resistance in vitro and shows a high replicative fitness in the presence of zidovudine. J Virol 78:7545ā7552
Geijtenbeek TB, Torensma R, van Vliet SJ, van Duijnhoven GC, Adema GJ, van Kooyk Y, Figdor CG (2000) Identification of DC-SIGN, a novel dendritic cell-specific ICAM-3 receptor that supports primary immune responses. Cell 100:575ā585
Gerondelis P, Archer RH, Palaniappan C, Reichman RC, Fay PJ, Bambara RA, Demeter LM (1999) The P236L delavirdine-resistant human immunodeficiency virus type 1 mutant is replication defective and demonstrates alterations in both RNA 5ā²-end-and DNA 3ā²-end-directed RNase H activities. J Virol 73:5803ā5813
Gonzalez LM, Brindeiro RM, Aguiar RS, Pereira HS, Abreu CM, Soares MA, Tanuri A (2004) Impact of nelfinavir resistance mutations on in vitro phenotype, fitness, and replication capacity of human immunodeficiency virus type 1 with subtype B and C proteases. Antimicrob Agents Chemother 48:3552ā3555
Goudsmit J, De Ronde A, Ho DD, Perelson AS (1996) Human immunodeficiency virus fitness in vivo: calculations based on a single zidovudine resistance mutation at codon 215 of reverse transcriptase. J Virol 70:5662ā5664
Goudsmit J, De Ronde A, de Rooij E, de Boer R (1997) Broad spectrum of in vivo fitness of human immunodeficiency virus type 1 subpopulations differing at reverse transcriptase codons 41 and 215. J Virol 71:4479ā4484
Goulder PJ, Watkins DI (2004) HIV and SIV CTL escape: implications for vaccine design. Nat Rev Immunol 4:630ā640
Goulder PJ, Phillips RE, Colbert RA, McAdam S, Ogg G, Nowak MA, Giangrande P, Luzzi G, Morgan B, Edwards A, McMichael AJ, Rowland-Jones S (1997) Late escape from an immunodominant cytotoxic T-lymphocyte response associated with progression to AIDS. Nat Med 3:212ā217
Goulder PJ, Altfeld MA, Rosenberg ES, Nguyen T, Tang Y, Eldridge RL, Addo MM, He S, Mukherjee JS, Phillips MN, Bunce M, Kalams SA, Sekaly RP, Walker BD, Brander C (2001) Substantial differences in specificity of HIV-specific cytotoxic T cells in acute and chronic HIV infection. J Exp Med 193:181ā194
Greenberg M, McDanal C, Stanfield-Oakley S, Jin L, Trembaly C, Sista P, Hirsch M, Matthews T (2001) Virus sensitivity to T-20 and T-1249 is independent of coreceptor usage. 8th Conference on Retroviruses and Opportunistic Infections
Gu Z, Gao Q, Fang H, Salomon H, Parniak MA, Goldberg E, Cameron J, Wainberg MA (1994) Identification of a mutation at codon 65 in the IKKK motif of reverse transcriptase that encodes human immunodeficiency virus resistance to 2ā²,3ā²-dideoxycytidine and 2ā²,3ā²-dideoxy-3ā²-thiacytidine. Antimicrob Agents Chemother 38:275ā281
Hahn BH, Shaw GM, De Cock KM, Sharp PM (2000) AIDS as a zoonosis: scientific and public health implications. Science 287:607ā614
Harrigan PR, Bloor S, Larder BA (1998) Relative replicative fitness of zidovudine-resistant human immunodeficiency virus type 1 isolates in vitro. J Virol 72:3773ā3778
Havlir DV, Eastman S, Gamst A, Richman DD (1996) Nevirapine-resistant human immunodeficiency virus: kinetics of replication and estimated prevalence in untreated patients. J Virol 70:7894ā7899
Hazuda DJ, Anthony NJ, Gomez RP, Jolly SM, Wai JS, Zhuang L, Fisher TE, Embrey M, Guare JP Jr, Egbertson MS, Vacca JP, Huff JR, Felock PJ, Witmer MV, Stillmock KA, Danovich R, Grobler J, Miller MD, Espeseth AS, Jin L, Chen IW, Lin JH, Kassahun K, Ellis JD, Wong BK, Xu W, Pearson PG, Schleif WA, Cortese R, Emini E, Summa V, Holloway MK, Young SD (2004a) A naphthyridine carboxamide provides evidence for discordant resistance between mechanistically identical inhibitors of HIV-1 integrase. Proc Natl Acad Sci U S A 101:11233ā11238
Hazuda DJ, Young SD, Guare JP, Anthony NJ, Gomez RP, Wai JS, Vacca JP, Handt L, Motzel SL, Klein HJ, Dornadula G, Danovich RM, Witmer MV, Wilson KA, Tussey L, Schleif WA, Gabryelski LS, Jin L, Miller MD, Casimiro DR, Emini EA, Shiver JW (2004b) Integrase inhibitors and cellular immunity suppress retroviral replication in rhesus macaques. Science 305:528ā532
Hertogs K, de Bethune MP, Miller V, Ivens T, Schel P, Van Cauwenberge A, Van Den EC, Van Gerwen V, Azijn H, Van Houtte M, Peeters F, Staszewski S, Conant M, Bloor S, Kemp S, Larder B, Pauwels R (1998) A rapid method for simultaneous detection of phenotypic resistance to inhibitors of protease and reverse transcriptase in recombinant human immunodeficiency virus type 1 isolates from patients treated with antiretroviral drugs. Antimicrob Agents Chemother 42:269ā276
Hirsch MS, Conway B, Dāaquila RT, Johnson VA, Brun-Vezinet F, Clotet B, Demeter LM, Hammer SM, Jacobsen DM, Kuritzkes DR, Loveday C, Mellors JW, Vella S, Richman DD (1998) Antiretroviral drug resistance testing in adults with HIV infection: implications for clinical management. International AIDS Society-USA Panel. JAMA 279:1984ā1991
Hirsch MS, Brun-Vezinet F, Dāaquila RT, Hammer SM, Johnson VA, Kuritzkes DR, Loveday C, Mellors JW, Clotet B, Conway B, Demeter LM, Vella S, Jacobsen DM, Richman DD (2000) Antiretroviral drug resistance testing in adult HIV-1 infection: recommendations of an International AIDS Society-USA Panel. JAMA 283:2417ā2426
Hirsch VM (2004) What can natural infection of African monkeys with simian immunodeficiency virus tell us about the pathogenesis of AIDS? AIDS Rev 6:40ā53
Ho DD, Toyoshima T, Mo H, Kempf DJ, Norbeck D, Chen CM, Wideburg NE, Burt SK, Erickson JW, Singh MK (1994) Characterization of human immunodeficiency virus type 1 variants with increased resistance to a C2-symmetric protease inhibitor. J Virol 68:2016ā2020
Ho DD, Neumann AU, Perelson AS, Chen W, Leonard JM, Markowitz M (1995) Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection. Nature (London) 373:123ā126
Holland JJ, de la Torre JC, Clarke DK, Duarte E (1991) Quantitation of relative fitness and great adaptability of clonal populations of RNA viruses. J Virol 65:2960ā2967
Holmes EC (2003) Patterns of intra-and interhost nonsynonymous variation reveal strong purifying selection in dengue virus. J Virol 77:11296ā11298
Holterman L, Niphuis H, Koornstra W, Dubbes R, ten Haaft P, Heeney JL (2000) The rate of progression to AIDS is independent of virus dose in simian immunodeficiency virus-infected macaques. J Gen Virol 81:1719ā1726
Hu DJ, Dondero TJ, Rayfield MA, George R, Schochetman G, Jaffe HW, Luo C, Kalish ML, Weniger BG, Pau C, Schable CA, Curran JW (1996) The emerging genetic diversity of HIV. The importance of global surveillance for diagnostics, research, and prevention. JAMA 275:210ā216
Hunt G, Tiemessen CT (2000) Occurrence of additional NF-kappaB-binding motifs in the long terminal repeat region of South African HIV type 1 subtype C isolates. AIDS Res Hum Retroviruses 16:305ā306
Iglesias-Ussel MD, Casado C, Yuste E, Olivares I, Lopez-Galindez C (2002) In vitro analysis of HIV-1 resistance to nevirapine and fitness determination of resistant variants. J Gen Virol 83:93ā101
Imamichi T, Berg SC, Imamichi H, Lopez JC, Metcalf JA, Falloon J, Lane HC (2000) Relative replication fitness of a high-level 3ā²-azido-3ā²-deoxythymidine-resistant variant of human immunodeficiency virus type 1 possessing an amino acid deletion at codon 67 and a novel substitution (ThrāGly) at codon 69. J Virol 74:10958ā10964
Imamichi T, Murphy MA, Imamichi H, Lane HC (2001) Amino acid deletion at codon 67 and Thr-to-Gly change at codon 69 of human immunodeficiency virus type 1 reverse transcriptase confer novel drug resistance profiles. J Virol 75:3988ā3992
Joag SV (2000) Primate models of AIDS. Microbes Infect 2:223ā229
Kalish ML, Baldwin A, Raktham S, Wasi C, Luo C-C, Schochetman G, Mastro TD, Young N, Vanichseni S, RĆ¼bsamen-Waigmann H, von Briesen H, Mullins JI, Delwart E, Herring B, Esparza J, Heyward WL, Osmanov S (1995) The evolving molecular epidemiology of HIV-1 envelope subtypes in injecting drug users in Bangkok, Thailand: implications for HIV vaccine trials. AIDS 9:851ā857
Kanki PJ, Hamel DJ, Sankale JL, Hsieh C, Thior I, Barin F, Woodcock SA, Gueye-Ndiaye A, Zhang E, Montano M, Siby T, Marlink R, NDoye I, Essex ME, Mboup S (1999) Human immunodeficiency virus type 1 subtypes differ in disease progression. J Infect Dis 179:68ā73
Kaslow RA, Carrington M, Apple R, Park L, Munoz A, Saah AJ, Goedert JJ, Winkler C, OāBrien SJ, Rinaldo C, Detels R, Blattner W, Phair J, Erlich H, Mann DL (1996) Influence of combinations of human major histocompatibility complex genes on the course of HIV-1 infection. Nat Med 2:405ā411
Kellam P, Larder BA (1994) Recombinant virus assay: a rapid, phenotypic assay for assessment of drug susceptibility of human immunodeficiency virus type 1 isolates. Antimicrob Agents Chemother 38:23ā30
Kelleher AD, Long C, Holmes EC, Allen RL, Wilson J, Conlon C, Workman C, Shaunak S, Olson K, Goulder P, Brander C, Ogg G, Sullivan JS, Dyer W, Jones I, McMichael AJ, Rowland-Jones S, Phillips RE (2001) Clustered mutations in HIV-1 gag are consistently required for escape from HLA-B27-restricted cytotoxic T lymphocyte responses. J Exp Med 193:375ā386
Keulen W, Nijhuis M, Schuurman R, Berkhout B, Boucher C (1997) Reverse transcriptase fidelity and HIV-1 variation. Science 275:229, author reply 230ā231
Kilby JM, Hopkins S, Venetta TM, DiMassimo B, Cloud GA, Lee JY, Alldredge L, Hunter E, Lambert D, Bolognesi D, Matthews T, Johnson MR, Nowak MA, Shaw GM, Saag MS (1998) Potent suppression of HIV-1 replication in humans by T-20, a peptide inhibitor of gp41-mediated virus entry. Nat Med 4:1302ā1307
Kimata JT, Kuller L, Anderson DB, Dailey P, Overbaugh J (1999) Emerging cytopathic and antigenic simian immunodeficiency virus variants influence AIDS progression. Nat Med 5:535ā541
Kirchhoff F, Greenough TC, Brettler DB, Sullivan JL, Desrosiers RC (1995) Brief report: absence of intact nef sequences in a long-term survivor with nonprogressive HIV-1 infection. N Engl J Med 332:228ā232
Knipe DM, Howley PM (2001) Fields virology, 4th edn. Lippincott Williams and Wilkins, Philadelphia
Kondrashov AS (1988) Deleterious mutations and the evolution of sexual reproduction. Nature (London) 336:435ā440
Kondrashov AS (1994) Mullerās ratchet under epistatic selection. Genetics 136:1469ā1473
Kondrashov AS, Crow JF (1991) Haploidy or diploidy: which is better? Nature (London) 351:314ā315
Korber B, Hahn B, Foley B, Mellors J, Leitner T, Myers G, McCutchan F, Kuiken C (1997a) Human retroviruses and AIDS 1997. Theoretical Biology and Biophysics Group, Los Alamos National Laboratory, Los Alamos, NM
Korber B, Hahn B, Foley B, Mellors JW, Leitner T, Myers G, McCutchan F, Kuiken C (1997b) Human retroviruses and AIDS. A compilation and analysis of nucleic acid and amino acid sequences. Theoretical Biology and Byophysics Group, Los Alamos National Laboratory, Los Alamos, NM
Korber B, Muldoon M, Theiler J, Gao F, Gupta R, Lapedes A, Hahn BH, Wolinsky S, Bhattacharya T (2000) Timing the ancestor of the HIV-1 pandemic strains [see comments]. Science 288:1789ā1796
Kosalaraksa P, Kavlick MF, Maroun V, Le R, Mitsuya H (1999) Comparative fitness of multi-dideoxynucleoside-resistant human immunodeficiency virus type 1 (HIV-1) in an in vitro competitive HIV-1 replication assay. J Virol 73:5356ā5363
Kozal MJ, Shah N, Shen N, Yang R, Fucini R, Merigan TC, Richman DD, Morris D, Hubbell E, Chee M, Gingeras TR (1996) Extensive polymorphisms observed in HIV-1 clade B protease gene using high-density oligonucleotide arrays. Nat Med 2:753ā759
Kuiken CL, Foley B, Hahn B, Korber B, McCutchan F, Marx P, Mellors J, Mullins JI, Sodroski J, Wolinsky S (1999) Human retroviruses and AIDS 1999: a compilation and analysis of nucleic acid and amino acid sequences. Theoretical Biology and Biophysics Group, Los Alamos National Laboratory, Los Alamos, NM
Kwa D, Vingerhoed J, Boeser B, Schuitemaker H (2003) Increased in vitro cytopathicity of CC chemokine receptor 5-restricted human immunodeficiency virus type 1 primary isolates correlates with a progressive clinical course of infection. J Infect Dis 187:1397ā1403
Larder B (2001) Mechanisms of HIV-1 drug resistance. AIDS 15Suppl 5:S27āS34
Larder BA, Kemp SD, Harrigan PR (1995) Potential mechanism for sustained antiretroviral efficacy of AZT-3TC combination therapy. Science 269:696ā699
Lazaro E, Escarmis C, Perez-Mercader J, Manrubia SC, Domingo E (2003) Resistance of virus to extinction on bottleneck passages: study of a decaying and fluctuating pattern of fitness loss. Proc Natl Acad Sci U S A 100:10830ā10835
Lech WJ, Wang G, Li Yang Y, Chee Y, Dorman K, McCrae D, Lazzeroni LC, Erickson JW, Sinsheimer JS, Kaplan AH (1996) In vivo sequence diversity of the protease of human immunodeficiency virus type 1: presence of protease inhibitor-resistant variants in untreated subjects. J Virol 70:2038ā2043
Lee DJ, Robinson WE Jr (2004) Human immunodeficiency virus type 1 (HIV-1) integrase: resistance to dike to acid integrase inhibitors impairs HIV-1 replication and integration and confers cross-resistance to L-chicoric acid. J Virol 78:5835ā5847
Leigh-Brown AJ (1997) Analysis of HIV-1 env gene sequences reveals evidence for a low effective number in the viral population. Proc Natl Acad Sci U S A 94:1862ā1865
Leigh Brown AJ, Frost SD, Mathews WC, Dawson K, Hellmann NS, Daar ES, Richman DD, Little SJ (2003) Transmission fitness of drug-resistant human immunodeficiency virus and the prevalence of resistance in the antiretroviral-treated population. J Infect Dis 187:683ā686
Lenski RE, May RM (1994) The evolution of virulence in parasites and pathogens: reconciliation between two competing hypotheses. J Theor Biol 169:253ā265
Leroux C, Cadore JL, Montelaro RC (2004) Equine infectious anemia virus (EIAV): what has HIVās country cousin got to tell us? Vet Res 35:485ā512
Little SJ, Daar ES, Dāaquila RT, Keiser PH, Connick E, Whitcomb JM, Hellmann NS, Petropoulos CJ, Sutton L, Pitt JA, Rosenberg ES, Koup RA, Walker BD, Richman DD (1999) Reduced antiretroviral drug susceptibility among patients with primary HIV infection [see comments]. JAMA 282:1142ā1149
Little SJ, Holte S, Routy JP, Daar ES, Markowitz M, Collier AC, Koup RA, Mellors JW, Connick E, Conway B, Kilby M, Wang L, Whitcomb JM, Hellmann NS, Richman DD (2002) Antiretroviral-drug resistance among patients recently infected with HIV. N Engl J Med 347:385ā394
Lole KS, Bollinger RC, Paranjape RS, Gadkari D, Kulkarni SS, Novak NG, Ingersoll R, Sheppard HW, Ray SC (1999) Full-length human immunodeficiency virus type 1 genomes from subtype C-infected seroconverters in India, with evidence of intersubtype recombination. J Virol 73:152ā160
Loveday C (2001) International perspectives on antiretroviral resistance. Nucleoside reverse transcriptase inhibitor resistance. J Acquir Immune Defic Syndr 26Suppl 1:S10āS24
Loveday C, Hill A (1995) Prediction of progression to AIDS with serum HIV-1 RNA and CD4 count. Lancet 345:790ā791
Lu J, Kuritzkes DR (2001) A novel recombinant marker virus assay for comparing the relative fitness of hiv-1 reverse transcriptase variants. J Acquir Immune Defic Syndr 27:7ā13
Lu J, Sista P, Giguel F, Greenberg M, Kuritzkes DR (2004) Relative replicative fitness of human immunodeficiency virus type 1 mutants resistant to enfuvirtide (T-20). J Virol 78:4628ā4637
Lukashov V, Goudsmit J (1997) Founder virus population related to route of virus transmission: a determinant of intrahost human immunodeficiency virus type 1 evolution? J Virol 71:2023ā2030
Maeda Y, Venzon DJ, Mitsuya H (1998) Altered drug sensitivity, fitness, and evolution of human immunodeficiency virus type 1 with pol gene mutations conferring multi-dideoxynucleoside resistance. J Infect Dis 177:1207ā1213
Mahanty S, Bray M (2004) Pathogenesis of filoviral haemorrhagic fevers. Lancet Infect Dis 4:487ā498
Mammano F, Petit C, Clavel F (1998) Resistance-associated loss of viral fitness in human immunodeficiency virus type 1: phenotypic analysis of protease and gag coevolution in protease inhibitor-treated patients. J Virol 72:7632ā7637
Mansky LM, Temin HM (1995) Lower in vivo mutation rate of human immunodeficiency virus type 1 than that predicted from the fidelity of purified reverse transcriptase. J Virol 69:5087ā5094
Margot NA, Isaacson E, McGowan I, Cheng AK, Schooley RT, Miller MD (2002) Genotypic and phenotypic analyses of HIV-1 in antiretroviral-experienced patients treated with tenofovir DF. AIDS 16:1227ā1235
Marozsan AJ, Moore D, Lobritz M, Fraundorf E, Abraha A, Reeves JD, Arts EJ (2005) Differences in the fitness of two diverse wild-type HIV-1 isolates are related to the efficiency of cell binding and entry. J Virol 79:7121ā7124
Martinez-Picado J, Savara AV, Shi L, Sutton L, Dāaquila RT (2000) Fitness of human immunodeficiency virus type 1 protease inhibitor-selected single mutants. Virology 275:318ā322
Martinez-Picado J, Savara AV, Sutton L, Dāaquila RT (1999) Replicative fitness of protease inhibitor-resistant mutants of human immunodeficiency virus type 1. J Virol 73:3744ā3752
Martinez-Picado J, Morales-Lopetegui K, Wrin T, Garcia-Prado J, Frost SD, Petropoulos CJ, Clotet B, Ruiz L (2001) Selection of the M184V mutation during repetitive cycles of structured antiretroviral treatment interruptions. 5th International Workshop on HIV Drug Resistance and Treatment Strategies, Scottsdale, Arizona June 2001, Abstract 36
McDonald D, Wu L, Bohks SM, KewalRamani VN, Unutmaz D, Hope TJ (2003) Recruitment of HIV and its receptors to dendritic cell-T cell junctions. Science 300:1295ā1297
Mellors JW, Rinaldo CR Jr, Gupta P, White RM, Todd JA, Kingsley LA (1996) Prognosis in HIV-1 infection predicted by the quantity of virus in plasma [see comments] [published erratum appears in Science 1997 Jan 3; 275(5296):14]. Science 272:1167ā1170
Menendez-Arias L, Este JA (2004) HIV-resistance to viral entry inhibitors. Curr Pharm Des 10:1845ā1860
Menzo S, Castagna A, Monachetti A, Hasson H, Danise A, Carini E, Bagnarelli P, Lazzarin A, Clementi M (2004) Genotype and phenotype patterns of human immunodeficiency virus type 1 resistance to enfuvirtide during long-term treatment. Antimicrob Agents Chemother 48:3253ā3259
Messenger SL, Molineux IJ, Bull JJ (1999) Virulence evolution in a virus obeys a tradeoff. Proc R Soc Lond B Biol Sci 266:397ā404
Migueles SA, Sabbaghian MS, Shupert WL, Bettinotti MP, Marincola FM, Martino L, Hallahan CW, Selig SM, Schwartz D, Sullivan J, Connors M (2000) HLA B*5701 is highly associated with restriction of virus replication in a subgroup of HIV-infected long term nonprogressors. Proc Natl Acad Sci U S A 97:2709ā2714
Miller V (2001) International perspectives on antiretroviral resistance. Resistance to protease inhibitors. J Acquir Immune Defic Syndr 26Suppl 1:S34āS50
Miralles R, Moya A, Elena SF (1997) Is group selection a factor modulating the virulence of RNA viruses? Genet Res 69:165ā172
Miralles R, Gerrish PJ, Moya A, Elena SF (1999a) Clonal interference and the evolution of RNA viruses. Science 285:1745ā1747
Miralles R, Moya A, Elena SF (1999b) Effect of population patchiness and migration rates on the adaptation and divergence of vesicular stomatitis virus quasispecies populations. J Gen Virol 80:2051ā2059
Miralles R, Moya A, Elena SF (2000) Diminishing returns of population size in the rate of RNA virus adaptation. J Virol 74:3566ā3571
Montefiori DC, Pantaleo G, Fink LM, Zhou JT, Zhou JY, Bilska M, Miralles GD, Fauci AS (1996) Neutralizing and infection-enhancing antibody responses to human immunodeficiency virus type 1 in long-term nonprogressors. J Infect Dis 173:60ā67
Moore FB, Rozen DE, Lenski RE (2000) Pervasive compensatory adaptation in Escherichia coli. Proc R Soc Lond B Biol Sci 267:515ā522
Moya A, Holmes EC, Gonzalez-Candelas F (2004) The population genetics and evolutionary epidemiology of RNA viruses. Nat Rev Microbiol 2:279ā288
Myint L, Matsuda M, Matsuda Z, Yokomaku Y, Chiba T, Okano A, Yamada K, Sugiura W (2004) Gag non-cleavage site mutations contribute to full recovery of viral fitness in protease inhibitor-resistant human immunodeficiency virus type 1. Antimicrob Agents Chemother 48:444ā452
Nelson JA, Baribaud F, Edwards T, Swanstrom R (2000) Patterns of changes in human immunodeficiency virus type 1 V3 sequence populations late in infection. J Virol 74:8494ā8501
Neumann T, Hagmann I, Lohrengel S, Heil ML, Derdeyn CA, Krausslich HG, Dittmar MT (2005) T20-insensitive HIV-1 from naive patients exhibits high viral fitness in a novel dual-color competition assay on primary cells. Virology 333:251ā262
Newstein MC, Desrosiers RC (2001) Effects of reverse-transcriptase mutations M184V and E89G on simian immunodeficiency virus in Rhesus monkeys. J Infect Dis 184:1262ā1267
Nijhuis M, Boucher CA, Schipper P, Leitner T, Schuurman R, Albert J (1998) Stochastic processes strongly influence HIV-1 evolution during suboptimal protease-inhibitor therapy. Proc Natl Acad Sci U S A 95:14441ā14446
Nijhuis M, Schuurman R, de Jong D, Erickson J, Gustchina E, Albert J, Schipper P, Gulnik S, Boucher CA (1999) Increased fitness of drug resistant HIV-1 protease as a result of acquisition of compensatory mutations during suboptimal therapy. AIDS 13:2349ā2359
Nijhuis M, Deeks S, Boucher C (2001) Implications of antiretroviral resistance on viral fitness. Curr Opin Infect Dis 14:23ā28
Novella IS, Duarte EA, Elena SF, Moya A, Domingo E, Holland JJ (1995a) Exponential increases of RNA virus fitness during large population transmissions. Proc Natl Acad Sci U S A 92:5841ā5844
Novella IS, Duarte EA, Elena SF, Moya A, Domingo E, Holland JJ (1995b) Exponential increases of RNA virus fitness during large population transmissions. Proc Natl Acad Sci U S A 92:5841ā5844
Novella IS, Ebendick-Corp (2004) Molecular basis of fitness loss and fitness recovery in vesicular stomatitis virus. J Mol Biol 342:1423ā1430
Novella IS, Elena SF, Moya A, Domingo E, Holland JJ (1995c) Size of genetic bottlenecks leading to virus fitness loss is determined by mean initial population fitness. J Virol 69:2869ā2872
Novella IS, Ball LA, Wertz GW (2004) Fitness analyses of vesicular stomatitis strains with rearranged genomes reveal replicative disadvantages. J Virol 78:9837ā9841
Nowak MA, Anderson RM, McLean AR, Wolfs TFW, Goudsmit J, May RM (1991) Antigenic diversity thresholds and the development of AIDS. Science 254:963ā969
OāBrien SJ, Moore JP (2000) The effect of genetic variation in chemokines and their receptors on HIV transmission and progression to AIDS. Immunol Rev 177:99ā111
OāConnor DH, Allen TM, Vogel TU, Jing P, DeSouza IP, Dodds E, Dunphy EJ, Melsaether C, Mothe B, Yamamoto H, Horton H, Wilson N, Hughes AL, Watkins DI (2002) Acute phase cytotoxic T lymphocyte escape is a hallmark of simian immunodeficiency virus infection. Nat Med 8:493ā499
Overbaugh J, Kreiss J, Poss M, Lewis P, Mostad S, John G, Nduati R, Mbori-Ngacha D, Martin H Jr, Richardson B, Jackson S, Neilson J, Long EM, Panteleeff D, Welch M, Rakwar J, Jackson D, Chohan B, Lavreys L, Mandaliya K, Ndinya-Achola J, Bwayo J (1999) Studies of human immunodeficiency virus type 1 mucosal viral shedding and transmission in Kenya. J Infect Dis 179[Suppl 3]:S401āS404
Pantaleo G, Menzo S, Vaccarezza M, Graziosi C, Cohen OJ, Demarest JF, Montefiori D, Orenstein JM, Fox C, Schrager LK, Margolick JB, Buchbinder S, Giorgi JV, Fauci AS (1995) Studies in subjects with long-term nonprogressive human immunodeficiency virus infection. N Eng J Med 332:209ā216
Park J, Morrow CD (1993) Mutations in the protease gene of human immunodeficiency virus type 1 affect release and stability of virus particles. Virology 194:843ā850
Partridge L, Barton NH (1993) Optimality, mutation and the evolution of ageing. Nature (London) 362:305ā311
Peeters M (2000) Recombinant HIV sequences: their role in the global epidemic. In: Kuiken C, Foley B, Hahn B, Korber B, McCutchan F, Marx P, Mellors J, Mullins JI, Sodroski J, Wolinsky S (eds) Human retroviruses and AIDS 2000. Theoretical Biology and Biophysics Group, Los Alamos National Laboratory, Los Alamos, NM, pp I-39āI-54
Perelson AS, Neumann AU, Markowitz M, Leonard JM, Ho DD (1996) HIV-1 dynamics in vivo: virion clearance rate, infected cell life-span, and viral generation time. Science 271:1582ā1586
Petropoulos CJ, Parkin NT, Limoli KL, Lie YS, Wrin T, Huang W, Tian H, Smith D, Winslow GA, Capon DJ, Whitcomb JM (2000) A novel phenotypic drug susceptibility assay for human immunodeficiency virus type 1. Antimicrob Agents Chemother 44:920ā928
Phillips RE, Rowland-Jones S, Nixon DF, Gotch FM, Edwards JP, Ogunlesi AO, Elvin JG, Rothbard JA, Bangham CR, Rizza CR (1991) Human immunodeficiency virus genetic variation that can escape cytotoxic T cell recognition. Nature (London) 354:453ā459
Picchio GR, Valdez H, Sabbe R, Landay AL, Kuritzkes DR, Lederman MM, Mosier DE (2000) Altered viral fitness of HIV-1 following failure of protease inhibitor-based therapy. J Acquir Immune Defic Syndr 25:289ā295
Piyasirisilp S, McCutchan FE, Carr JK, Sanders-Buell E, Liu W, Chen J, Wagner R, Wolf H, Shao Y, Lai S, Beyrer C, Yu XF (2000) A recent outbreak of human immunodeficiency virus type 1 infection in southern China was initiated by two highly homogeneous, geographically separated strains, circulating recombinant form AE and a novel BC recombinant. J Virol 74:11286ā11295
Pontesilli O, Klein MR, Kerkhof-Garde SR, Pakker NG, de Wolf F, Schuitemaker H, Miedema F (1998) Longitudinal analysis of human immunodeficiency virus type 1-specific cytotoxic T lymphocyte responses: a predominant gag-specific response is associated with nonprogressive infection. J Infect Dis 178:1008ā1018
Prado JG, Wrin T, Beauchaine J, Ruiz L, Petropoulos CJ, Frost SD, Clotet B, Dāaquila RT, Martinez-Picado J (2002) Amprenavir-resistant HIV-1 exhibits lopinavir crossresistance and reduced replication capacity. AIDS 16:1009ā1017
Prado JG, Franco S, Matamoros T, Ruiz L, Clotet B, Menendez-Arias L, Martinez MA, Martinez-Picado J (2004) Relative replication fitness of multi-nucleoside analogue-resistant HIV-1 strains bearing a dipeptide insertion in the fingers subdomain of the reverse transcriptase and mutations at codons 67 and 215. Virology 326:103ā112
Precious HM, Gunthard HF, Wong JK, Dāaquila RT, Johnson VA, Kuritzkes DR, Richman DD, Leigh Brown AJ (2000) Multiple sites in HIV-1 reverse transcriptase associated with virological response to combination therapy. AIDS 14:31ā36
Preston BD, Poiesz BJ, Loeb LA (1988) Fidelity of HIV-1 reverse transcriptase. Science 242:1168ā1171
Quinn TC (1996) Global burden of the HIV pandemic. Lancet 348:99ā106
QuiƱones-Mateu ME, Arts EJ (1999)Recombination in HIV-1: update and implications. AIDS Reviews 1:89ā100
QuiƱones-Mateu ME, Arts EJ (2001) HIV-1 fitness: implications for drug resistance, disease progression, and global epidemic evolution. In: Kuiken C, Foley B, Hahn B, Marx P, McCutchan F, Mellors J, Wolinsky S, Korber B (eds) HIV Sequence Compendium 2001. Theoretical Biology and Biophysics Group, Los Alamos National Laboratory, Los Alamos, NM, pp 134ā170
QuiƱones-Mateu ME, Arts EJ (2002) Fitness of drug resistant HIV-1: methodology and clinical implications. Drug Resist Updat 5:224ā233
QuiƱones-Mateu ME, Ball SC, Marozsan AJ, Torre VS, Albright JL, Vanham G, van der Groen G, Colebunders RL, Arts EJ (2000) A dual infection/competition assay shows a correlation between ex vivo human immunodeficiency virus type 1 fitness and disease progression. J Virol 74:9222ā9233
QuiƱones-Mateu ME, Tadele M, Parera M, Mas A, Weber J, Rangel HR, Chakraborty B, Clotet B, Domingo E, Menendez-Arias L, Martinez MA (2002) Insertions in the reverse transcriptase increase both drug resistance and viral fitness in a human immunodeficiency virus type 1 isolate harboring the multi-nucleoside reverse transcriptase inhibitor resistance 69 insertion complex mutation. J Virol 76:10546ā10552
Rangel HR, Weber J, Chakraborty B, Gutierrez A, Marotta ML, Mirza M, Kiser P, Martinez MA, Este JA, QuiƱones-Mateu ME (2003) Role of the human immunodeficiency virus type 1 envelope gene in viral fitness. J Virol 77:9069ā9073
Resch W, Parkin N, Stuelke EL, Watkins T, Swanstrom R (2001) Amultiple-site-specific heteroduplex tracking assay as a tool for the study of viral population dynamics. Proc Natl Acad Sci U S A 98:176ā181
Rey-Cuille MA, Berthier JL, Bomsel-Demontoy MC, Chaduc Y, Montagnier L, Hovanessian AG, Chakrabarti LA (1998) Simian immunodeficiency virus replicates to high levels in sooty mangabeys without inducing disease. J Virol 72:3872ā3886
Richardson BA, Mbori-Ngacha D, Lavreys L, John-Stewart GC, Nduati R, Panteleeff DD, Emery S, Kreiss JK, Overbaugh J (2003) Comparison of human immunodeficiency virus type 1 viral loads in Kenyan women, men, and infants during primary and early infection. J Virol 77:7120ā7123
Richman DD, Wrin T, Little SJ, Petropoulos CJ (2003) Rapid evolution of the neutralizing antibody response to HIV type 1 infection. Proc Natl Acad Sci U S A 100:4144ā4149
Robinson LH, Myers RE, Snowden BW, Tisdale M, Blair ED (2000) HIV type 1 protease cleavage site mutations and viral fitness: implications for drug susceptibility phenotyping assays. AIDS Res Hum Retroviruses 16:1149ā1156
Rodenburg CM, Li Y, Trask SA, Chen Y, Decker J, Robertson DL, Kalish ML, Shaw GM, Allen S, Hahn BH, Gao F (2001) Near full-length clones and reference sequences for subtype C isolates of HIV type 1 from three different continents. AIDS Res Hum Retroviruses 17:161ā168
Root MJ, Kay MS, Kim PS (2001) Protein design of an HIV-1 entry inhibitor. Science 291:884ā888
Rose RE, Gong YF, Greytok JA, Bechtold CM, Terry BJ, Robinson BS, Alam M, Colonno RJ, Lin PF (1996) Human immunodeficiency virus type 1 viral background plays a major role in development of resistance to protease inhibitors. Proc Natl Acad Sci U S A 93:1648ā1653
Rosenberg ES, Billingsley JM, Caliendo AM, Boswell SL, Sax PE, Kalams SA, Walker BD (1997) Vigorous HIV-1-specific CD4+ T cell responses associated with control of viremia [see comments]. Science 278:1447ā1450
Rouzine IM, Coffin JM (1999) Linkage disequilibrium test implies a large effective population number for HIV in vivo. Proc Natl Acad Sci U S A 96:10758ā10763
Ruiz-Jarabo CM, Miller E, Gomez-Mariano G, Domingo E (2003) Synchronous loss of quasispecies memory in parallel viral lineages: a deterministic feature of viral quasispecies. J Mol Biol 333:553ā563
Sanjuan R, Moya A, Elena SF (2004) The contribution of epistasis to the architecture of fitness in an RNA virus. Proc Natl Acad Sci U S A 101:15376ā15379
Santiago ML, Santiago EG, Hafalla JC, Manalo MA, Orantia L, Cajimat MN, Martin C, Cuaresma C, Dominguez CE, Borromeo ME, De Groot AS, Flanigan TP, Carpenter CC, Mayer KH, Ramirez BL (1998) Molecular epidemiology of HIV-1 infection in the Philippines, 1985 to 1997: transmission of subtypes B and E and potential emergence of subtypes C and F. J Acquir Immune Defic Syndr Hum Retrovirol 18:260ā269
Santra S, Schmitz JE, Kuroda MJ, Lifton MA, Nickerson CE, Lord CI, Pal R, Franchini G, Letvin NL (2002) Recombinant canarypox vaccine-elicited CTL specific for dominant and subdominant simian immunodeficiency virus epitopes in rhesus monkeys. J Immunol 68:1847ā1853
Schuitemaker H, Koot M, Kootstra NA, Dercksen MW, de Goede RE, van Steenwijk RP, Lange JM, Schattenkerk JK, Miedema F, Tersmette M (1992) Biological phenotype of human immunodeficiency virus type 1 clones at different stages of infection: progression of disease is associated with a shift from monocytotropic to T-cell-tropic virus population. J Virol 66:1354ā1360
Seo TK, Thorne JL, Hasegawa M, Kishino H (2002) Estimation of effective population size of HIV-1 within a host: a pseudomaximum-likelihood approach. Genetics 160:1283ā1293
Shafer RW, Dupnik K, Winters MA, Eshleman SH (2000) A guide to HIV-1 reverse transcriptase and protease sequencing for drug resistance studies. HIV Sequence Compendium 2000.
Shankarappa R, Margolick JB, Gange SJ, Rodrigo AG, Upchurch D, Farzadegan H, Gupta P, Rinaldo CR, Learn GH, He X, Huang XL, Mullins JI (1999) Consistent viral evolutionary changes associated with the progression of human immunodeficiency virus type 1 infection. J Virol 73:10489ā10502
Sharma PL, Crumpacker CS (1997) Attenuated replication of human immunodeficiency virus type 1 with a didanosine-selected reverse transcriptase mutation [published erratum appears in J Virol 1998; 72:3504]. J Virol 71:8846ā8851
Sharma PL, Crumpacker CS (1999) Decreased processivity of human immunodeficiency virus type 1 reverse transcriptase (RT) containing didanosine-selectedmutation Leu74Val: a comparative analysis of RT variants Leu74Val and lamivudine-selected Met184Val. J Virol 73:8448ā8456
Shi C, Mellors JW (1997) A recombinant retroviral system for rapid in vivo analysis of human immunodeficiency virus type 1 susceptibility to reverse transcriptase inhibitors. Antimicrob Agents Chemother 41:2781ā2785
Shirasaka T, Kavlick MF, Ueno T, Gao WY, Kojima E, Alcaide ML, Chokekijchai S, Roy BM, Arnold E, Yarchoan R (1995) Emergence of human immunodeficiency virus type 1 variants with resistance to multiple dideoxynucleosides in patients receiving therapy with dideoxynucleosides. Proc Natl Acad Sci USA 92:2398ā2402
Shriner D, Shankarappa R, Jensen MA, Nickle DC, Mittler JE, Margolick JB, Mullins JI (2004) Influence of random genetic drift on human immunodeficiency virus type 1 env evolution during chronic infection. Genetics 166:1155ā1164
Siller S (2001) Sexual selection and the maintenance of sex. Nature (London) 411:689ā692
Simmonds P (2004) Genetic diversity and evolution of hepatitis C virusā15 years on. J Gen Virol 85:3173ā3188
Simmons G, Clapham PR, Picard L, Offord RE, Rosenkilde MM, Schwartz TW, Buser R, Wells TN, Proudfoot AE (1997) Potent inhibition of HIV-1 infectivity in macrophages and lymphocytes by a novel CCR5 antagonist. Science 276:276ā279
Simon V, Padte N, Murray D, Vanderhoeven J, Wrin T, Parkin N, Di Mascio M, Markowitz M (2003) Infectivity and replication capacity of drug-resistant human immunodeficiency virus type 1 variants isolated during primary infection. J Virol 77:7736ā7745
Sole RV, Ferrer R, Gonzalez-Garcia I, Quer J, Domingo E (1999) Red queen dynamics, competition and critical points in a model of RNA virus quasispecies. J Theor Biol 198:47ā59
Soto-Ramirez LE, Renjifo B, McLane MF, Marlink R, OāHara C, Sutthent R, Wasi C, Vithayasai P, Vithayasai V, Apichartpiyakul C, Auewarakul P, Pena Cruz V, Chui DS, Osathanondh R, Mayer K, Lee TH, Essex M (1996) HIV-1 Langerhansā cell tropism associated with heterosexual transmission of HIV. Science 271:1291ā1293
Stapleton JT (2003) GB virus type C/hepatitis G virus. Semin Liver Dis 23:137ā148
Svarovskaia ES, Barr R, Zhang X, Pais GC, Marchand C, Pommier Y, Burke TR Jr, Pathak VK (2004) Azido-containing diketo acid derivatives inhibit human immunodeficiency virus type 1 integrase in vivo and influence the frequency of deletions at two-long-terminal-repeat-circle junctions. J Virol 78:3210ā3222
Tamiya S, Mardy S, Kavlick MF, Yoshimura K, Mistuya H (2004) Amino acid insertions near Gag cleavage sites restore the otherwise compromised replication of human immunodeficiency virus type 1 variants resistant to protease inhibitors. J Virol 78:12030ā12040
Tang JW, Pillay D (2004) Transmission of HIV-1 drug resistance. J Clin Virol 30:1ā10
Temin HM (1989) Is HIV unique or merely different? J Acquir Immune Defic Syndr 2:1ā9
Tersmette M, de Goede RE, Al BJ, Winkel IN, Gruters RA, Cuypers HT, Huisman HG, Miedema F (1988) Differential syncytium-inducing capacity of human immunodeficiency virus isolates: frequent detection of syncytium-inducing isolates in patients with acquired immunodeficiency syndrome (AIDS) and AIDS-related complex. J Virol 62:2026ā2032
Tersmette M, Miedema F (1990) Interactions between HIV and the host immune system in the pathogenesis of AIDS. AIDS 4:S57āS66
Troyer R, Collins KR, Abraha A, Fraundorf E, Moore D, Krizan RW, Toossi Z, Colebunders RL, Jensen MA, Mullins JI, Vanham G, Arts EJ (2005) Impact of ex vivo HIV-1 fitness and genetic diversity on disease progression. J Virol 79 (in press)
Turner PE, Chao L (1999) Prisonerās dilemma in an RNA virus. Nature (London) 398:441ā443
Turner PE, Elena SF (2000) Cost of host radiation in an RNA virus. Genetics 156:1465ā1470
Van Harmelen JH, van der RE, Loubser AS, York D, Madurai S, Lyons S, Wood R, Williamson C (1999) A predominantly HIV type 1 subtype C-restricted epidemic in South African urban populations. AIDS Res Hum Retroviruses 15:395ā398
Van Harmelen J, Williamson C, Kim B, Morris L, Carr J, Karim SS, McCutchan F (2001) Characterization of full-length HIV type 1 subtype Csequences from South Africa. AIDS Res Hum Retroviruses 17:1527ā1531
Velazquez-Campoy A, Todd MJ, Vega S, Freire E (2001) Catalytic efficiency and vitality of HIV-1 proteases from African viral subtypes. Proc Natl Acad Sci U S A 98:6062ā6067
Weaver SC, Brault AC, Kang W, Holland JJ (1999) Genetic and fitness changes accompanying adaptation of an arbovirus to vertebrate and invertebrate cells. J Virol 73:4316ā4326
Weber J, Rangel HR, Chakraborty B, Marotta ML, Valdez H, Fransen K, Florence E, Connick E, Smith K, Colebunders R, Landay A, Kuritzkes DR, Lederman MM, Vanham G, QuiƱones-Mateu ME (2003a) Role of baseline pol genotype in HIV-1 fitness evolution. JAIDS 33:448ā460
Weber J, Rangel HR, Chakraborty B, Tadele M, Martinez MA, Martinez-Picado J, Marotta ML, Mirza M, Ruiz L, Clotet B, Wrin T, Petropoulos CJ, QuiƱones-Mateu ME (2003b) A novel TaqMan real-time PCR assay to estimate ex vivo human immunodeficiency virus type 1 fitness in the era of multi-target (pol and env) antiretroviral therapy. J Gen Virol 84:2217ā2228
Weber J, Chakraborty B, Weberova J, Miller MD, QuiƱones-Mateu ME (2005) Diminished replicative fitness of primary human immunodeficiency virus type 1 isolates harboring the K65R mutation. J Clin Microbiol 43:1395ā1400
Wei X, Ghosh SK, Taylor ME, Johnson VA, Emini EA, Deutsch P, Lifson JD, Bonhoeffer S, Nowak MA, Hahn BH (1995) Viral dynamics in human immunodeficiency virus type 1 infection. Nature (London) 373:117ā122
Wei X, Decker JM, Liu H, Zhang Z, Arani RB, Kilby JM, Saag MS, Wu X, Shaw GM, Kappes JC (2002) Emergence of resistant human immunodeficiency virus type 1 in patients receiving fusion inhibitor (T-20) monotherapy. Antimicrob Agents Chemother 46:1896ā1905
Wei X, Decker JM, Wang S, Hui H, Kappes JC, Wu X, Salazar-Gonzalez JF, Salazar MG, Kilby JM, Saag MS, Komarova NL, Nowak MA, Hahn BH, Kwong PD, Shaw GM (2003) Antibody neutralization and escape by HIV-1. Nature (London) 422:307ā312
Whetter LE, Ojukwu IC, Novembre FJ, Dewhurst S (1999) Pathogenesis of simian immunodeficiency virus infection. J Gen Virol 80:1557ā1568
White HD, Robbins MD, Green WR (1990) Mechanism of escape of endogenous murine leukemia virus emv-14 from recognition by anti-AKR/Gross virus cytolytic T lymphocytes. J Virol 64:2608ā2619
White KL, Margot NA, Wrin T, Petropoulos CJ, Miller MD, Naeger LK (2002) Molecular mechanisms of resistance to human immunodeficiency virus type 1 with reverse transcriptase mutations K65R and K65R+M184V and their effects on enzyme function and viral replication capacity. Antimicrob Agents Chemother 46:3437ā3446
Winston A, Mandalia S, Pillay D, Gazzard B, Pozniak A (2002) The prevalence and determinants of the K65R mutation in HIV-1 reverse transcriptase in tenofovirnaive patients. AIDS 16:2087ā2089
Wodarz D, Nowak MA (1998) The effect of different immune responses on the evolution of virulent CXCR4-tropic HIV. Proc R Soc Lond B Biol Sci 265:2149ā2158
Wolinsky SM, Wike CM, Korber BT, Hutto C, Parks WP, Rosenblum LL, Kunstman KJ, Furtado MR, Munoz JL (1992) Selective transmission of human immunodeficiency virus type-1 variants from mothers to infants [see comments]. Science 255:1134ā1137
Wrin T, Gamarnik A, Whitehurst N, Beauchaine J, Whitcomb JM, Hellmann NS, Petropoulos CJ (2001) Natural variation of replication capacity measurements in drug-naive/susceptible HIV-1. 5th International Workshop on HIV Drug Resistance and Treatment Strategies, Scottsdale, Arizona June 2001, Abstract 24
Yoshimura K, Feldman R, Kodama E, Kavlick MF, Qiu YL, Zemlicka J, Mitsuya H (1999) In vitro induction of human immunodeficiency virus type 1 variants resistant to phosphoralaninate prodrugs of Z-methylenecyclopropane nucleoside analogues. Antimicrob Agents Chemother 43:2479ā2483
Yuste E, Sanchez-Palomino S, Casado C, Domingo E, Lopez-Galindez C (1999) Drastic fitness loss in human immunodeficiency virus type 1 upon serial bottleneck events. J Virol 73:2745ā2751
Yuste E, Lopez-Galindez C, Domingo E (2000) Unusual distribution of mutations associated with serial bottleneck passages of human immunodeficiency virus type 1. J Virol 74:9546ā9552
Zennou V, Mammano F, Paulous S, Mathez D, Clavel F (1998) Loss of viral fitness associated with multiple Gag and Gag-Pol processing defects in human immunodeficiency virus type 1 variants selected for resistance to protease inhibitors in vivo. J Virol 72:3300ā3306
Zhang D, Caliendo AM, Eron JJ, DeVore KM, Kaplan JC, Hirsch MS, Dāaquila RT (1994) Resistance to 2ā²,3ā²-dideoxycytidine conferred by a mutation in codon 65 of the human immunodeficiency virus type 1 reverse transcriptase. Antimicrob Agents Chemother 38:282ā287
Zhang H, Zhou Y, Alcock C, Kiefer T, Monie D, Siliciano J, Li Q, Pham P, Cofrancesco J, Persaud D, Siliciano RF (2004) Novel single-cell-level phenotypic assay for residual drug susceptibility and reduced replication capacity of drug-resistant human immunodeficiency virus type 1. J Virol 78:1718ā1729
Zhang YM, Imamichi H, Imamichi T, Lane HC, Falloon J, Vasudevachari MB, Salzman NP (1997) Drug resistance during indinavir therapy is caused by mutations in the protease gene and in its Gag substrate cleavage sites. J Virol 71:6662ā6670
Zhu T, Mo H, Wang N, Nam DS, Cao Y, Koup RA, Ho DD (1993) Genotypic and phenotypic characterization of HIV-1 patients with primary infection. Science 261:1179ā1181
Zhu T, Wang N, Carr A, Nam DS, Moor-Jankowski R, Cooper DA, Ho DD (1996) Genetic characterization of human immunodeficiency virus type 1 in blood and genital secretions: evidence for viral compartmentalization and selection during sexual transmission. J Virol 70:3098ā3107
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
Ā© 2006 Springer-Verlag Berlin Heidelberg
About this chapter
Cite this chapter
QuiƱones-Mateu, M.E., Arts, E.J. (2006). Virus Fitness: Concept, Quantification, and Application to HIV Population Dynamics. In: Domingo, E. (eds) Quasispecies: Concept and Implications for Virology. Current Topics in Microbiology and Immunology, vol 299. Springer, Berlin, Heidelberg. https://doi.org/10.1007/3-540-26397-7_4
Download citation
DOI: https://doi.org/10.1007/3-540-26397-7_4
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-540-26395-1
Online ISBN: 978-3-540-26397-5
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)